BDR Pharma unveils idiopathic pulmonary fibrosis drug Nintedanib in India
IPF is lung disorder where there is scarring of the lungs due to an unknown cause, BDR Pharmaceuticals said in a statement.
New Delhi: BDR Pharmaceuticals on Monday said it has launched the generic version of Nintedanib drug for treatment of Idiopathic Pulmonary Fibrosis (IPF).
The generic version of the drug has been launched under the brand name ''Nintenib'' in the country.
IPF is a lung disorder where there is scarring of the lungs due to an unknown cause, BDR Pharmaceuticals said in a statement.
"We are proud to launch the generic version of the drug for lung fibrosis in India especially during a time when there is an ardent need of the medicine for COVID-19 patients," BDR Pharmaceuticals CMD Dharmesh Shah said.
Read also: BDR Pharma to launch COVID drug Favipiravir at Rs 99 per tablet in India
The company''s drug is priced at Rs 750 (100 mg) and Rs 900 (150 mg) for a pack of 10 tablets, the company said.
Currently, there are two clinical trials being conducted to study the safety and efficacy of Nintedanib for the treatment of moderately to critically ill COVID-19 patients suffering from IPF, it added.
Read also: BDR Pharma unveils prostate cancer drug enzalutamide at Rs 24480 per pack in India
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.